MCID: CNN004
MIFTS: 40

Connective Tissue Cancer malady

Categories: Cancer diseases

Aliases & Classifications for Connective Tissue Cancer

Aliases & Descriptions for Connective Tissue Cancer:

Name: Connective Tissue Cancer 12 14
Neoplasms, Connective Tissue 42 69
Neoplasm of Connective Tissues 12
Tumour of Connective Tissue 12
Connective Tissue Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:201
MeSH 42 D009372
SNOMED-CT 64 126598008 254821003
UMLS 69 C0027656

Summaries for Connective Tissue Cancer

Disease Ontology : 12 A musculoskeletal system cancer that is located in connective tissue.

MalaCards based summary : Connective Tissue Cancer, also known as neoplasms, connective tissue, is related to fibrosarcoma and connective tissue benign neoplasm. An important gene associated with Connective Tissue Cancer is EWSR1 (EWS RNA Binding Protein 1), and among its related pathways/superpathways are Glioma and Pathways in cancer. The drugs Desogestrel and Dienogest have been mentioned in the context of this disorder. Affiliated tissues include connective tissue, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and pigmentation

Related Diseases for Connective Tissue Cancer

Diseases in the Connective Tissue Cancer family:

Connective Tissue Benign Neoplasm

Diseases related to Connective Tissue Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 86)
id Related Disease Score Top Affiliating Genes
1 fibrosarcoma 31.5 CD34 CREB3L2 EWSR1 KIT
2 connective tissue benign neoplasm 11.1
3 spindle cell sarcoma 10.7
4 pleural cancer 10.7
5 kaposi sarcoma 10.7
6 chondrosarcoma 10.7
7 papillary ependymoma 10.4 SSX1 SSX2B
8 rohhad 10.4 COL1A1 PDGFB
9 neurofibroma of gallbladder 10.4 CD34 KIT
10 gallbladder leiomyosarcoma 10.4 CD34 KIT
11 rommen mueller sybert syndrome 10.4 CDK4 MDM2 TP53
12 chondroid lipoma 10.4 CD68 KIT
13 vitreous syneresis 10.4 CD99 EWSR1
14 lung hilum cancer 10.4 CD34 CD99
15 linitis plastica 10.4 CD68 TP53
16 house allergic alveolitis 10.4 CDK4 MDM2 TP53
17 bone leiomyosarcoma 10.4 CD34 CDK4 MDM2
18 extranodal nasal nk/t cell lymphoma 10.4 CDK4 EWSR1 KIT
19 congenital muscular dystrophy with hyperlaxity 10.3 CD99 EWSR1 FUS
20 peripheral osteosarcoma 10.3 CD99 EWSR1 PDGFB
21 blood protein disease 10.3 CD68 CDK4 MDM2
22 ossifying fibromyxoid tumor 10.3 CD34 CDK4 TP53
23 vascular myelopathy 10.3 CD34 MDM2 TP53
24 tibial aplasia ectrodactyly hydrocephalus 10.3 CD99 KIT
25 speech disorder 10.3 CD34 KIT
26 coronary restenosis 10.3 EWSR1 FUS KIT
27 arteriosclerosis obliterans 10.3 CD34 TP53
28 intraorbital meningioma 10.3 CD68 MDM2 TP53
29 cerebellopontine angle meningioma 10.3 CD34 SSX1
30 acantholytic squamous cell skin carcinoma 10.3 CD34 CREB3L2 TP53
31 small intestinal sarcoma 10.3 CREB3L2 KIT MDM2
32 adult spinal cord ependymoma 10.3 CD34 CD68
33 papillary serous adenocarcinoma 10.3 CD34 SS18 SSX2B
34 interstitial lung disease 10.3 CDK4 MDM2 TP53
35 prostate rhabdomyosarcoma 10.3 CDK4 EWSR1 TP53
36 heavy chain disease 10.3 CD34 CD68 EWSR1
37 freemartinism 10.3 CD34 CD68 KIT
38 pharynx cancer 10.3 CD34 KIT TP53
39 colorectal cancer 1 10.3 CREB3L2 EWSR1 FUS
40 extraocular retinoblastoma 10.3 CDK4 MDM2 TP53
41 rhabdomyosarcoma 2, alveolar 10.3 CDK4 EWSR1 MDM2
42 enchondromatosis dwarfism deafness 10.3 CDK4 KIT MDM2 TP53
43 brain stem angioblastoma 10.3 CD34 CDK4 MDM2 TP53
44 integumentary system benign neoplasm 10.3 CDK4 MDM2 TP53
45 adenosarcoma 10.3 CDK4 KIT MDM2 TP53
46 breast squamous cell carcinoma 10.3 CD34 CD68 TP53
47 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 3 10.3 CDK4 KIT MDM2 TP53
48 neutrophil immunodeficiency syndrome 10.3 CD34 COL1A1 PDGFB TP53
49 glucosephosphate isomerase deficiency 10.3 CDK4 MDM2 PDGFB TP53
50 multifocal osteogenic sarcoma 10.3 CDK4 CREB3L2 KIT MDM2

Graphical network of the top 20 diseases related to Connective Tissue Cancer:



Diseases related to Connective Tissue Cancer

Symptoms & Phenotypes for Connective Tissue Cancer

GenomeRNAi Phenotypes related to Connective Tissue Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 9.98 TLE1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-112 9.98 FUS
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 9.98 CDK4
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.98 SSX2B
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.98 SSX2B
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-203 9.98 EWSR1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 9.98 SSX1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.98 EWSR1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.98 FUS
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.98 CDK4 EWSR1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.98 FUS TLE1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.98 FUS SSX1 SSX2B TLE1 CDK4 EWSR1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.98 EWSR1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.98 EWSR1
15 Decreased substrate adherent cell growth GR00193-A-1 9.32 KIT PDGFB
16 Decreased substrate adherent cell growth GR00193-A-2 9.32 CDK4 KIT PDGFB
17 Decreased substrate adherent cell growth GR00193-A-3 9.32 CDK4 PDGFB
18 Decreased substrate adherent cell growth GR00193-A-4 9.32 CDK4 KIT PDGFB

MGI Mouse Phenotypes related to Connective Tissue Cancer:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 pigmentation MP:0001186 9.43 CDK4 COL1A1 KIT MDM2 PDGFB TP53
2 renal/urinary system MP:0005367 9.17 MDM2 PDGFB TP53 CAMKMT CDK4 COL1A1

Drugs & Therapeutics for Connective Tissue Cancer

Drugs for Connective Tissue Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 757)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Desogestrel Approved Phase 4 54024-22-5 40973
2 Dienogest Approved Phase 4 65928-58-7
3
Goserelin Approved Phase 4,Phase 3 65807-02-5 47725 5311128
4
Nandrolone Approved, Experimental, Illicit Phase 4 434-22-0, 62-90-8 9904 229455
5
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
6
Aminolevulinic acid Approved Phase 4,Phase 2 106-60-5 137
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
8
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
9
Polidocanol Approved Phase 4 9002-92-0
10
Adalimumab Approved Phase 4,Phase 2,Phase 3 331731-18-1 16219006
11
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2 428863-50-7
12
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 185243-69-0
13
Infliximab Approved Phase 4,Phase 3,Phase 2 170277-31-3
14
Ranibizumab Approved Phase 4 347396-82-1 459903
15
Calcium carbonate Approved Phase 4,Phase 3 471-34-1
16
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
17
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
18
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
19
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 57-27-2 5288826
20
Tamoxifen Approved Phase 4,Phase 2,Phase 1 10540-29-1 2733526
21
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
22
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
23
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
24
Diphenhydramine Approved Phase 4,Phase 2,Phase 3,Phase 1 58-73-1, 147-24-0 3100
25
Promethazine Approved Phase 4,Phase 2,Phase 3,Phase 1 60-87-7 4927
26
Bleomycin Approved Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
27
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
28
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
29
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 155213-67-5 392622
30
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
31
Etoposide Approved Phase 4,Phase 3,Phase 1,Phase 2 33419-42-0 36462
32
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
33
Mechlorethamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-75-2 4033
34
Cisplatin Approved Phase 4,Phase 2,Phase 3,Phase 1 15663-27-1 84093 441203 2767
35
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
36
Gemcitabine Approved Phase 4,Phase 2,Phase 3,Phase 1 95058-81-4 60750
37
Cetrorelix Approved, Investigational Phase 4 120287-85-6 16129715 25074887
38
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
39
Zinc Approved Phase 4,Phase 2 7440-66-6 32051 23994
40
Zinc oxide Approved Phase 4,Phase 2 1314-13-2
41
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 1 137-58-6 3676
42
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
43
Ethanol Approved Phase 4,Phase 1,Phase 2 64-17-5 702
44
Acetaminophen Approved Phase 4,Phase 2,Phase 1 103-90-2 1983
45
Ibuprofen Approved Phase 4,Phase 2 15687-27-1 3672
46
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
47
Ropivacaine Approved Phase 4,Phase 3,Phase 2 84057-95-4 71273 175805
48
Abatacept Approved Phase 4,Phase 3,Phase 2,Phase 1 332348-12-6 10237
49
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
50
Histamine Approved, Investigational Phase 4,Phase 2 75614-87-8, 51-45-6 774

Interventional clinical trials:

(show top 50) (show all 2276)
id Name Status NCT ID Phase
1 MyoSure Hysteroscopic Tissue Removal System Registry Study Unknown status NCT01369758 Phase 4
2 High Intensity Focused Ultrasound Ablation Virus Myomectomy to Treat Uterine Fibroids Unknown status NCT01239641 Phase 4
3 Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin Unknown status NCT01738724 Phase 4
4 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4
5 Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion Unknown status NCT00313066 Phase 4
6 The Hysteroscopic Morcellator (HM). Unknown status NCT01537822 Phase 4
7 Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate Unknown status NCT01491711 Phase 4
8 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4
9 An Assessment of Intra-lesional 3% Polidocanol Solution in the Treatment of Digital Myxoid Cyst Unknown status NCT02154789 Phase 4
10 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Unknown status NCT00815282 Phase 4
11 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4
12 Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema Unknown status NCT02055911 Phase 4
13 Imatinib in KIT-negative Systemic Mastocytosis Completed NCT01297777 Phase 4
14 Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators Completed NCT00743080 Phase 4
15 Novel MRI Strategies as a Non-invasive Biomarker in Women With Uterine Fibroids Completed NCT00746031 Phase 4
16 Fibroids in Women of Reproductive Age and Women Pregnancy Completed NCT02620345 Phase 4
17 Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization Completed NCT02293447 Phase 4
18 Safety Study of ExAblate for the Treatment of Uterine Fibroids Completed NCT01142791 Phase 4
19 Safety Trial of Magnetic Resonance (MR) Guided Focused Ultrasound Surgery (FUS) in Women With Uterine Fibroids Wishing to Pursue Pregnancy in the Future Completed NCT00180739 Phase 4
20 MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids Completed NCT00166270 Phase 4
21 Efficacy Study of Magnetic Resonance (MR) Guided Focused Ultrasound in the Treatment of Large Fibroids Completed NCT00159328 Phase 4
22 Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor Completed NCT00793871 Phase 4
23 Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate Completed NCT00510354 Phase 4
24 Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST) Completed NCT00171977 Phase 4
25 Physical Characteristics of Retrieved Massive Allografts Completed NCT00160758 Phase 4
26 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients Completed NCT01402089 Phase 4
27 A Prospective Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Completed NCT00628901 Phase 4
28 HLA Sensitization Following Major Cortical Allograft Bone Procedures Completed NCT00160719 Phase 4
29 Intravenous or Intra-abdominal Local Anesthetics for Postoperative Pain Management. Completed NCT01492179 Phase 4
30 Efficacity Assessment of PREVADH® in Adhesion Prevention in Gynaecologic Surgery Completed NCT01388907 Phase 4
31 Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer Completed NCT00999921 Phase 4
32 Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure Completed NCT02227316 Phase 4
33 Sleep Quality After Stellate-ganglion Block of Patients Undergoing Breast Cancer Operation Completed NCT02651519 Phase 4
34 A Study to Determine the Number of Participants With Rheumatoid Arthritis (RA) Who Meet the Requirements for Treatment With Anti‐Tumor Necrosis Factor α (TNFα) in a General Hospital Setting in Korea Completed NCT01294722 Phase 4
35 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4
36 Anti-TNF Agents for the Treatment of Rheumatoid Arthritis Completed NCT00837434 Phase 4
37 Humira in Rheumatoid Arthritis - Do Bone Erosions Heal? Completed NCT00696059 Phase 4
38 SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. Completed NCT01295151 Phase 4
39 23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy Completed NCT02196480 Phase 4
40 Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis Completed NCT00420927 Phase 4
41 A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study Completed NCT02049112 Phase 4
42 Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice Completed NCT01692899 Phase 4
43 A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA) Completed NCT01163747 Phase 4
44 A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis Completed NCT01382940 Phase 4
45 A Long-term Safety Study of Infliximab (Remicade) Completed NCT00261976 Phase 4
46 Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial Completed NCT01400516 Phase 4
47 A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis Completed NCT01089023 Phase 4
48 Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients Completed NCT01022905 Phase 4
49 Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA) Completed NCT01382160 Phase 4
50 Acute Effect of Resistance Training in Inflammatory Markers in Women With Rheumatoid Arthritis Completed NCT02401958 Phase 4

Search NIH Clinical Center for Connective Tissue Cancer

Cochrane evidence based reviews: neoplasms, connective tissue

Genetic Tests for Connective Tissue Cancer

Anatomical Context for Connective Tissue Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Connective Tissue Cancer:

18
Connective Tissue

Publications for Connective Tissue Cancer

Articles related to Connective Tissue Cancer:

id Title Authors Year
1
Adherence to treatment guidelines for primary sarcomas affects patient survival: a side study of the European CONnective TIssue CAncer NETwork (CONTICANET). ( 23446092 )
2013
2
Long-term effects of connective tissue cancer treatment. ( 15346055 )
2004

Variations for Connective Tissue Cancer

Expression for Connective Tissue Cancer

Search GEO for disease gene expression data for Connective Tissue Cancer.

Pathways for Connective Tissue Cancer

GO Terms for Connective Tissue Cancer

Biological processes related to Connective Tissue Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hemopoiesis GO:0030097 9.43 CD34 KIT PDGFB
2 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.32 MDM2 PDGFB
3 paracrine signaling GO:0038001 9.16 CD34 PDGFB
4 positive regulation of gene expression GO:0010628 9.1 CD34 KIT MDM2 PDGFB TLE1 TP53
5 cellular response to actinomycin D GO:0072717 8.96 MDM2 TP53

Molecular functions related to Connective Tissue Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.33 COL1A1 KIT TP53
2 identical protein binding GO:0042802 9.17 COL1A1 EWSR1 FUS MDM2 PDGFB TLE1
3 platelet-derived growth factor binding GO:0048407 8.96 COL1A1 PDGFB

Sources for Connective Tissue Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....